Cite
HARVARD Citation
Danese, S. et al. (n.d.). DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. Journal of Crohn's and colitis. pp. S061-S062. [Online].